Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

BACKGROUND: In the pivotal phase III 2-year ADVANCE study, subcutaneous peginterferon beta-1a 125 mcg every 2 weeks demonstrated significant improvements in clinical outcomes, including disability endpoints, in patients with relapsing–remitting multiple sclerosis (RRMS). Here, we aim to further eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Neurol Disord
Main Authors: Newsome, Scott D., Kieseier, Bernd C., Liu, Shifang, You, Xiaojun, Kinter, Elizabeth, Hung, Serena, Sperling, Bjoern
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400156/
https://ncbi.nlm.nih.gov/pubmed/28450894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616676065
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados